PCM
NBIX icon

Peregrine Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Peregrine Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57,578
Closed -$8.17M – 311
2025
Q4 		$8.17M Sell
57,578
-1,266
-2% -$183K 0.25% 114
2025
Q3 		$8.26M Sell
58,844
-8,225
-12% -$1.11M 0.25% 110
2025
Q2 		$8.43M Sell
67,069
-5,903
-8% -$677K 0.25% 105
2025
Q1 		$8.07M Buy
72,972
+8,132
+13% +$1.03M 0.27% 100
2024
Q4 		$8.85M Buy
64,840
+1,159
+2% +$143K 0.26% 96
2024
Q3 		$7.34M Sell
63,681
-3,976
-6% -$545K 0.22% 124
2024
Q2 		$9.31M Buy
67,657
+881
+1% +$121K 0.27% 82
2024
Q1 		$9.21M Sell
66,776
-672
-1% -$91.8K 0.26% 93
2023
Q4 		$8.89M Sell
67,448
-11,625
-15% -$1.34M 0.27% 105
2023
Q3 		$8.9M Sell
79,073
-14,298
-15% -$1.51M 0.27% 133
2023
Q2 		$8.8M Buy
93,371
+8,754
+10% +$855K 0.24% 166
2023
Q1 		$8.56M Buy
84,617
+16,663
+25% +$1.73M 0.25% 178
2022
Q4 		$8.12M Sell
67,954
-17,780
-21% -$2.08M 0.25% 187
2022
Q3 		$9.11M Sell
85,734
-5,579
-6% -$566K 0.29% 144
2022
Q2 		$8.9M Sell
91,313
-72
-0.1% -$6.64K 0.27% 161
2022
Q1 		$8.57M Sell
91,385
-6,553
-7% -$555K 0.2% 202
2021
Q4 		$8.34M Buy
+97,938
New +$9.01M 0.17% 225

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Peregrine Capital Management's NBIX Position: Q1 2026 in Review

Peregrine Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 57,578 shares — an estimated $8.17M sold.

Peregrine Capital Management first reported a position in NBIX in Q4 2021 and held it in 17 quarters. The position peaked at $9.31M in Q2 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Peregrine Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Peregrine Capital Management sold 57,578 Neurocrine Biosciences shares in Q1 2026, an estimated $8.17M.
  • Peregrine Capital Management first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 17 quarters.
  • Peregrine Capital Management's Neurocrine Biosciences position peaked at $9.31M in Q2 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Peregrine Capital Management's 13F filing for Q1 2026, filed 23 Apr 2026.